Trial Profile
An Open-Label, Single-Arm Study of The Efficacy, Safety, and Pharmacokinetic Behavior of Leuprolide Mesylate Injectable Suspension (LMIS 25 mg) in Subjects With Prostate Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Leuprorelin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Foresee Pharmaceuticals
- 30 Apr 2019 This trial has been completed in Slovakia as per European Clinical Trials Database record.
- 21 Feb 2019 Primary endpoint has been met. (Efficacy of Leuprolide Mesylate (LMIS 25mg)), according to a Foresee Pharmaceuticals media release.
- 21 Feb 2019 Topline results presented in a Foresee Pharmaceuticals media release.